Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson & Johnson CEO Joaquin Duato said.

Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers. For the period, J&J posted operational sales growth of 4.2% to $21.9 billion.

Expect more pronounced impact from newly launched products as the year progresses; STELARA biosimilar competition to ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on JNJ: Disclaimer & Disclosure Report an Issue Johnson & Johnson NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $91 billion to $91.8 billion. This story was generated by Automated Insights ( ...